At PROCOMCURE work is done on novel compounds with activity against antibiotics-resistant bacterial infections. This work addresses a high medical and public health need. These promising antibacterial agents are of a new chemical class and show activity against gram-positive bacteria, such as staphylococci, streptococci, enterococci, and antibiotics-resistant and multidrug-resistant strains of these organisms. Both product- and medical use patents have been filed: WO/2016/087615, WO/2016/087616, and WO/2016/087618. The compounds interfere with steps in membrane-lipid biosynthesis and show low rates of resistance development.
PROCOMCURE’s patented technology for identifying peptides blocking protein-protein interactions is used to identify and select inhibitors that serve as novel antibacterial scaffolds (see section on Technology). Selection uses mutagenesis protocols to obtain high-affinity binders to a defined bacterial target-protein (WO/2009/027495) and quantitative analysis of inhibition using the procedures described for validation of protein-protein interactions.
PROCOMCURE would welcome opportunities to collaborate with partners with medicinal chemistry expertise to advance these drug discovery programs.